Mingchao Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mingchao Ding has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Jichao Chen
Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China
4 shared publications Joshua S. Fleishman
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York, NY, United States
4 shared publicationsYulin Li
Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China
4 shared publicationsYuwei Cao
Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China
4 shared publicationsZhe Zhang
Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China
4 shared publicationsYonglin Zhu
Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China
3 shared publications
Latest Publications
- Open Access
- 25 March 2026
- Published by Springer Nature in Cancer Cell International
- Vol. 26 (1)
Ferroptosis targeting: a novel therapeutic armamentarium in multiple myeloma
Multiple myeloma (MM), a hematological malignancy characterized by abnormal plasma cell proliferation, remains incurable because of its pervasive resistanc
- 25 March 2026
- Published by Springer Nature in Cancer Cell International
- Vol. 26 (1)
Open AccessFerroptosis targeting: a novel therapeutic armamentarium in multiple myeloma
Multiple myeloma (MM), a hematological malignancy characterized by abnormal plasma cell proliferation, remains incurable because of its pervasive resistanc
- 5 August 2025
- Published by Elsevier in Ageing Research Reviews
- Vol. 112, 102856
Strategies to rescue mitochondria in Parkinson’s disease: The significance of mitochondrial transfer
- 5 August 2025
- Published by Elsevier in Ageing Research Reviews
- Vol. 112, 102856
Strategies to rescue mitochondria in Parkinson’s disease: The significance of mitochondrial transfer
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 5835-5853
cGAS-STING Targeting Offers Novel Therapeutic Opportunities in Liver Diseases
Cyclic GMP/AMP (cGAMP) synthase (cGAS), coupled with the endoplasmic reticulum (ER)-anchored adaptor protein stimulator of interferon genes (STING), constitute key components of the type 1 interferon signaling network. cGAS detects both pathogen-derived DNA and aberrant cytosolic self-DNA, establishing the cGAS-STING pathway as a central player in autoimmune disorders, sterile inflammation, and senescence-related processes. However, sustained abnormal activation of this signaling axis is implicated in the pathogenesis of chronic inflammatory and autoimmune conditions. Recent studies have uncovered the pivotal role of cGAS-STING signaling in driving inflammation-associated pathologies, particularly hepatic disorders. Advances in understanding the molecular dynamics of this pathway have facilitated the development of targeted small-molecule inhibitors with therapeutic potential for cGAS-STING-driven liver diseases. In this review, we first delineate the core architecture of the cGAS-STING signaling cascade. Building on this framework, we analyze emerging evidence elucidating the mechanistic contributions of cGAS-STING activation to hepatic pathophysiology. Subsequently, we catalog pharmacologically active compounds capable of modulating this pathway in liver disease models. Finally, we critically evaluate current challenges in translating cGAS-STING-targeted therapies and propose strategic approaches to address these limitations. This synthesis underscores innovative therapeutic opportunities arising from precision modulation of the cGAS-STING axis in liver diseases.
- 1 July 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 5835-5853
Open AccesscGAS-STING Targeting Offers Novel Therapeutic Opportunities in Liver Diseases
Cyclic GMP/AMP (cGAMP) synthase (cGAS), coupled with the endoplasmic reticulum (ER)-anchored adaptor protein stimulator of interferon genes (STING), constitute key components of the type 1 interferon signaling network. cGAS detects both pathogen-derived DNA and aberrant cytosolic self-DNA, establishing the cGAS-STING pathway as a central player in autoimmune disorders, sterile inflammation, and senescence-related processes. However, sustained abnormal activation of this signaling axis is implicated in the pathogenesis of chronic inflammatory and autoimmune conditions. Recent studies have uncovered the pivotal role of cGAS-STING signaling in driving inflammation-associated pathologies, particularly hepatic disorders. Advances in understanding the molecular dynamics of this pathway have facilitated the development of targeted small-molecule inhibitors with therapeutic potential for cGAS-STING-driven liver diseases. In this review, we first delineate the core architecture of the cGAS-STING signaling cascade. Building on this framework, we analyze emerging evidence elucidating the mechanistic contributions of cGAS-STING activation to hepatic pathophysiology. Subsequently, we catalog pharmacologically active compounds capable of modulating this pathway in liver disease models. Finally, we critically evaluate current challenges in translating cGAS-STING-targeted therapies and propose strategic approaches to address these limitations. This synthesis underscores innovative therapeutic opportunities arising from precision modulation of the cGAS-STING axis in liver diseases.
- Open Access
- 9 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1579832
The activation of cGAS-STING pathway offers novel therapeutic opportunities in cancers
The cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway are crucial elements of the type I interferon (type I IFN) response. cGAS senses both exogenous and endogenous DNA within cells, labeling cGAS-STING as a pivotal anti-tumor immunity mechanism, autoimmunity, sterile inflammatory responses, and cellular senescence. The cGAS-STING pathway, a pivotal innate immune axis, modulates tumorigenesis via diverse effector responses. Emerging evidence have shown that activating of cGAS-STING pathway functions as a therapy to kill cancers. Insights into the biology of the cGAS-STING pathway have enabled the discovery of small-molecule agents which have the potential to activate cGAS-STING axis in cancers. In this review, we first outline the principal components of the cGAS-STING signaling cascade. Then we explore recent advancements in understanding the cGAS-STING signaling pathway, with particular emphasis on its activation mechanisms and roles in tumor cancer killing. Next, we summarize a list of bioactive small-molecule compounds which activate the cGAS-STING axis, reviewing their potential applications. Finally, we discuss key limitations of this new proposed therapeutic approach and provide possible techniques to overcome them. This review highlights a novel groundbreaking therapeutic possibilities through activating cGAS-STING in cancers.
- 9 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1579832
Open AccessThe activation of cGAS-STING pathway offers novel therapeutic opportunities in cancers
The cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway are crucial elements of the type I interferon (type I IFN) response. cGAS senses both exogenous and endogenous DNA within cells, labeling cGAS-STING as a pivotal anti-tumor immunity mechanism, autoimmunity, sterile inflammatory responses, and cellular senescence. The cGAS-STING pathway, a pivotal innate immune axis, modulates tumorigenesis via diverse effector responses. Emerging evidence have shown that activating of cGAS-STING pathway functions as a therapy to kill cancers. Insights into the biology of the cGAS-STING pathway have enabled the discovery of small-molecule agents which have the potential to activate cGAS-STING axis in cancers. In this review, we first outline the principal components of the cGAS-STING signaling cascade. Then we explore recent advancements in understanding the cGAS-STING signaling pathway, with particular emphasis on its activation mechanisms and roles in tumor cancer killing. Next, we summarize a list of bioactive small-molecule compounds which activate the cGAS-STING axis, reviewing their potential applications. Finally, we discuss key limitations of this new proposed therapeutic approach and provide possible techniques to overcome them. This review highlights a novel groundbreaking therapeutic possibilities through activating cGAS-STING in cancers.
- Open Access
- 9 December 2024
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 66 (1) , 1-15
Non‑coding RNA‑mediated epigenetic modification of ferroptosis in non‑small cell lung cancer (Review)
Ferroptosis is a novel form of regulated cell death that plays a key role in inhibiting tumor malignancy. The ferroptosis signalling cascade provides new opportunities for lung cancer therapy. Non‑coding RNA (ncRNA)‑mediated epigenetic modification can influence the vulnerability of cancer cells to ferroptosis in non‑small‑cell lung cancer (NSCLC). The present review describes the core molecular mechanisms underlying ferroptosis and the role of epigenetic mechanisms in regulating ferroptosis in NSCLC, as well as developments in understanding the ncRNA‑induced mechanisms that affect ferroptosis in NSCLC. The present review aimed to enhance understanding of the epigenetic mechanisms mediated by ncRNAs that modulate ferroptosis in NSCLC, highlighting a novel therapeutic strategy for NSCLC via the ncRNA‑ferroptosis axis.
- 9 December 2024
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 66 (1) , 1-15
Open AccessNon‑coding RNA‑mediated epigenetic modification of ferroptosis in non‑small cell lung cancer (Review)
Ferroptosis is a novel form of regulated cell death that plays a key role in inhibiting tumor malignancy. The ferroptosis signalling cascade provides new opportunities for lung cancer therapy. Non‑coding RNA (ncRNA)‑mediated epigenetic modification can influence the vulnerability of cancer cells to ferroptosis in non‑small‑cell lung cancer (NSCLC). The present review describes the core molecular mechanisms underlying ferroptosis and the role of epigenetic mechanisms in regulating ferroptosis in NSCLC, as well as developments in understanding the ncRNA‑induced mechanisms that affect ferroptosis in NSCLC. The present review aimed to enhance understanding of the epigenetic mechanisms mediated by ncRNAs that modulate ferroptosis in NSCLC, highlighting a novel therapeutic strategy for NSCLC via the ncRNA‑ferroptosis axis.
- Open Access
- 5 June 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 176, 116878
Pharmacologically inducing anoikis offers novel therapeutic opportunities in hepatocellular carcinoma
- 5 June 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 176, 116878
Open AccessPharmacologically inducing anoikis offers novel therapeutic opportunities in hepatocellular carcinoma
- Top Cited Papers
- 1 June 2024
- Published by Elsevier in Drug Resistance Updates
- Vol. 75, 101099
Targeting anoikis resistance as a strategy for cancer therapy
- 1 June 2024
- Published by Elsevier in Drug Resistance Updates
- Vol. 75, 101099
Top Cited PapersTargeting anoikis resistance as a strategy for cancer therapy
- Open Access
- 20 July 2022
- Published by Medknow in Journal of Minimal Access Surgery
- Vol. 18 (4) , 560-566
A meta-analysis of combined generic-covered stent-graft with or without bare-metal stent for refractory variceal bleeding
Objectives: The meta-analysis was conducted to systematically assess the efficacy and safety of generic stent-graft/bare-stent combination compared with Fluency stent alone in transjugular intrahepatic portosystemic shunt procedure for refractory variceal bleeding. Methods: PubMed, EMBASE, Scopus, Web of Science and the Cochrane Database were searched for relevant studies from January 1990 to September 2020; outcome measures studied were primary patency, hepatic encephalopathy, survival, re-bleeding and portal venous pressure. Results: Four studies (1 randomised controlled trial and 3 retrospective studies) with 449 subjects (157 patients in the combined stent group and 292 patients in the covered stent group) were included. No significant difference was observed in the incidence of mortality (hazard ratio [HR] = 1.069, 95% confidence interval [CI] [0.524, 2.178]), hepatic encephalopathy (odds ratio [OR] = 0.860, 95% CI [0.341, 2.169], P = 0.750) and re-bleeding (OR = 1.049, 95% CI [0.226, 4.881], P = 0.951). Compared with Fluency stent alone, combination therapy was associated with moderate decrease in outcomes on the post-operative portal venous pressure (standard mean difference [SMD] −0.210, 95% CI [−0.418, −0.001], P = 0.049) and was not associated with significant decrease in outcomes on the pre-operative portal venous pressure (SMD − 0.129, 95% CI [−0.336, 0.078], P = 0.223). The primary patency was significantly lower in the Fluency/bare-stent combination group (HR = 0.473, 95% CI [0.288, 0.776]). Conclusions: Generic stent-graft/bare-stent combination therapy was associated with significantly lower primary patency compared to Fluency stent alone.
- 20 July 2022
- Published by Medknow in Journal of Minimal Access Surgery
- Vol. 18 (4) , 560-566
Open AccessA meta-analysis of combined generic-covered stent-graft with or without bare-metal stent for refractory variceal bleeding
Objectives: The meta-analysis was conducted to systematically assess the efficacy and safety of generic stent-graft/bare-stent combination compared with Fluency stent alone in transjugular intrahepatic portosystemic shunt procedure for refractory variceal bleeding. Methods: PubMed, EMBASE, Scopus, Web of Science and the Cochrane Database were searched for relevant studies from January 1990 to September 2020; outcome measures studied were primary patency, hepatic encephalopathy, survival, re-bleeding and portal venous pressure. Results: Four studies (1 randomised controlled trial and 3 retrospective studies) with 449 subjects (157 patients in the combined stent group and 292 patients in the covered stent group) were included. No significant difference was observed in the incidence of mortality (hazard ratio [HR] = 1.069, 95% confidence interval [CI] [0.524, 2.178]), hepatic encephalopathy (odds ratio [OR] = 0.860, 95% CI [0.341, 2.169], P = 0.750) and re-bleeding (OR = 1.049, 95% CI [0.226, 4.881], P = 0.951). Compared with Fluency stent alone, combination therapy was associated with moderate decrease in outcomes on the post-operative portal venous pressure (standard mean difference [SMD] −0.210, 95% CI [−0.418, −0.001], P = 0.049) and was not associated with significant decrease in outcomes on the pre-operative portal venous pressure (SMD − 0.129, 95% CI [−0.336, 0.078], P = 0.223). The primary patency was significantly lower in the Fluency/bare-stent combination group (HR = 0.473, 95% CI [0.288, 0.776]). Conclusions: Generic stent-graft/bare-stent combination therapy was associated with significantly lower primary patency compared to Fluency stent alone.